Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest ...

Even $149 a month, the advertised price for a starting dose of a still-in-development GLP-1 pill on TrumpRx, will be too big ...

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling ...

Historical trends show that even leading firms can experience abrupt market fluctuations, where stocks can plummet ...

Managing obesity with both drugs and lifestyle changes ‘enables clinicians to treat patients holistically, long-term, and in ...

Eli Lilly is dropping CVS Health's drug benefit plan for its employees after the healthcare conglomerate stopped covering the ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

Eli Lilly shares have room to keep going as GLP-1 drugs spread their reach.